<DOC>
	<DOCNO>NCT02556502</DOCNO>
	<brief_summary>The diagnosis Alzheimer 's disease ( AD ) base clinical neuropathological criterion . Some patient contributive CSF biology determinate high level risk AD ( Tau + phospho-tau ratio increase Ab42 / decrease Aβ40 ) , others intermediate CSF biology ( Tau and/or phospho-tau increase Ab42 ratio / normal Aβ40 ) unclassifiable . 18F-Florbetaben ( Neuraceq® ) , radioisotope positron emission tomography ( PET ) , selectively bind amyloid plaque , high detection sensitivity ( 98 % ) . Detection amyloid plaque PET image separate patient accord criterion Dubois , AD allow benefit cholinesterase inhibitor treatment . If negative , diagnosis AD exclude high level confidence prevent initiate unnecessary treatment , expensive community . This first imaging study amyloid plaque target population whose diagnosis AD uncertain accord CSF biology . The aim study describe result amyloid PET case intermediate CSF biology separate patient AD accord criterion Dubois</brief_summary>
	<brief_title>18F-Florbetaben PET Amyloid Imaging Case Intermediate CSF Biology Diagnosis Alzheimer 's Disease : Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Major subject give consent participate study . Patients suspect AD whose CSF marker give intermediate result ( CSF punction le 6 month ) : meaning tau and/or phosphotau increase Ab42 / Aβ40 normal ( Ab42 / Aβ40 &gt; 0.07 ) . Nonindication perform PET 18FFlorbetaben . Affiliation french social security . Patients guardianship . Inability perform PET 18FFlorbetaben ( agitate patient , confuse , .. ) . Pregnancy , lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>